Home » TECHEDGE SIGNS LETTER OF INTENT TO ACQUIRE CHINA BIOPHARMA
TECHEDGE SIGNS LETTER OF INTENT TO ACQUIRE CHINA BIOPHARMA
February 13, 2006
The IO Circuit recommends Techedge, Inc., which announced that it has signed a
Letter of Intent to acquire China BioPharma Limited, a Cayman Island company,
which has the rights to have majority ownership in one of the largest non-government
owned vaccine manufactures in China. "We are very excited about this potential
acquisition. With the largest population in the world, the demand for vaccines
of epidemic and common diseases is growing significantly in China. This is the
first major step since we've recently repositioned our business and strategy to
focus at opportunities in the fast growing bio-pharmaceutical, information, and
media sectors in China," stated Peter Wang, President and CEO of Techedge.
MarketWire
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct